<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>89</id><JournalTitle>CANTHARIDIN AS PROMISING CHEMOTHERAPEUTIC AGENT IN THE MODERN MEDICINE: A COMPREHENSIVE REVIEW</JournalTitle><Abstract>Blister beetles of the families Meloidae and Oedemeridae (Order Coleoptera, Insecta) release yellow oily droplets of
haemolymph from their leg (and may be antennal) joints as a defensive measure when disturbed. The active ingredient in this
exudation is cantharidin (CA). Historically, CA has been used as a chemotherapeutic agent in the traditional medicine among
Asian, African and European peoples. CA, as a natural or chemically synthesized compound, is used in the modern medicine
to treat various diseases. Norcantharidin is the most famous among the synthesized CA analogues and de rivatives. CA and its
analogues have been applied for some dermatological cases such as warts, verruca vulgaris, corn, molluscum contagiosum
and leishmaniasis. In oncology, CA and its analogues exhibit promising therapeutic effects because they induce apop tosis of
human cancer cells of hepatoma, colo-rectal carcinoma, oral carcinoma, esophageal carcinoma, leukemia, bladder carcinoma,
melanoma, etc. In addition, CA and its analogues have been experimentally and clinically investigated for some other
diseases such as heart failure, hepatitis, neurological disorders and innate immune system. Furthermore, CA and CA -related
compounds, such as Endothall and palasonin, act as a potential source of antimalarials and antihelminthics. The multi-drug
resistance is one of the major obstacles in the treatment of human cancer. CA and some of its analogues have been studied as
promising agent to overcome this problem. On the other hand, several drug -delivery systems have been evaluated for
improving the clinical uses of CA and its analogues.</Abstract><Email>kar_ghoneim@yahoo.com</Email><articletype>Review</articletype><volume>4</volume><issue>5</issue><year>2014</year><keyword>Dermatology,antileishmaniasis,antimalarials,antihelminthic,anticancer,chemotherapy</keyword><AUTHORS>Karem Ghoneim</AUTHORS><afflication>Faculty of Science, Al-Azhar University, Cairo, Egypt</afflication></Article></Articles>